| Japanese |
|---|
| Title | がんの核医学診断 |
|---|
| Subtitle | 総説 |
|---|
| Authors | 遠藤啓吾* |
|---|
| Authors(kana) | |
|---|
| Organization | *群馬大学医学部核医学科 |
|---|
| Journal | 核医学 |
|---|
| Volume | 32 |
|---|
| Number | 10 |
|---|
| Page | 1125-1130 |
|---|
| Year/Month | 1995/10 |
|---|
| Article | 報告 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」がんの核医学診断に主として用いられている放射性医薬品は, いまなお67Gaと201Tlである. 脳, 心臓の分野では新しい診断薬が次々と発売されているのに対し, がんの分野ではこれまで新しく開発される放射性医薬品は少なかった. 逆に言えば新しい放射性医薬品の開発が最も待たれている分野でもある. 古くからの131I(甲状腺癌)のほか, 131I-MIBG(褐色細胞腫など)のほか, 111In-Octreotide(消化器内分泌腫瘍など)などの新しい診断薬も臨床に用いられるようになった. 89Srは骨転移による疼痛の緩和に有用である. さらにこれまでPET専用カメラで撮影されていた18F-FDGが, SPECT装置でも撮影されるようになった. この18F-FDGのSPECTは, 一般病院でも簡便に利用されるため, これからのがんの診療に大きなインパクトを与えるものと期待される. 新しい放射性医薬品の開発とともに, がんの診断, 治療への核医学応用は今後ますます発展するものと思われる. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | 67Ga, 201Tl, 99mTc(V)DMSA, 18F-FDG, Nuclear Oncology. |
|---|
| English |
|---|
| Title | Current Status of Nuclear Oncology in Japan |
|---|
| Subtitle | |
|---|
| Authors | Keigo ENDO |
|---|
| Authors(kana) | |
|---|
| Organization | Department of Nuclear Medicine, Gunma University Hospital |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 32 |
|---|
| Number | 10 |
|---|
| Page | 1125-1130 |
|---|
| Year/Month | 1995/10 |
|---|
| Article | Report |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | The most commonly used radionuclides for cancer patients in Japan have been still 67Ga and 201Tl chloride. In addition to the diagnosis of lung cancer and thyroid tumor, 201Tl is recently applied to patients with brain tumor, bone and soft tissue tumor and parathynoid adenoma. Comparing to Nuclear Cardiology and Brain Nuclear Medicine, where many new radiopharmaceuticals have been developed, there are few new drugs in Nuclear Oncology. In other words, new radiopharmaceuticals are expected to be developed for the diagnosis and/or therapy of cancer. In addition to 131I for thyroid cancer, new radiopharmaceuticals such as 111In-octreotide and 99mTc(V)-DMSA have been clinically employed. In spite of strong expectation, radiolabeled monoclonal antibodies have not been clinically used in Japan. However, the technique of humanized antibodies has been established and in U.S.A., 131I-labeled antibodies are reported to be effective for the treatment of malignant lymphoma. 89Sr is useful for the relief of bone pain caused by the bone metastasis. New findings that SPECT of 18F-FDG, a positron emitter, has been revealed to have a great potential in the management of cancer patients, will give a great impact on Nuclear Oncology. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | 67Ga, 201Tl, 99mTc(V)DMSA, 18F-FDG, Nuclear Oncology. |
|---|